Cargando…
A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea
In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we perf...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445957/ https://www.ncbi.nlm.nih.gov/pubmed/34531426 http://dx.doi.org/10.1038/s41598-021-97664-y |
_version_ | 1784568769508540416 |
---|---|
author | Kang, Ka-Won Song, Ji Eun Lee, Byung-Hyun Jeon, Min Ji Yu, Eun Sang Kim, Dae Sik Lee, Se Ryeon Sung, Hwa Jung Choi, Chul Won Park, Yong Kim, Byung Soo |
author_facet | Kang, Ka-Won Song, Ji Eun Lee, Byung-Hyun Jeon, Min Ji Yu, Eun Sang Kim, Dae Sik Lee, Se Ryeon Sung, Hwa Jung Choi, Chul Won Park, Yong Kim, Byung Soo |
author_sort | Kang, Ka-Won |
collection | PubMed |
description | In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines. |
format | Online Article Text |
id | pubmed-8445957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84459572021-09-20 A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea Kang, Ka-Won Song, Ji Eun Lee, Byung-Hyun Jeon, Min Ji Yu, Eun Sang Kim, Dae Sik Lee, Se Ryeon Sung, Hwa Jung Choi, Chul Won Park, Yong Kim, Byung Soo Sci Rep Article In clinical practice, most patients with monoclonal gammopathy of undetermined significance (MGUS) undergo long-term follow-up without disease progression. There is insufficient real-world data about how closely and whether anything other than disease progression should be monitored. Herein, we performed a nationwide study of 470 patients with MGUS with a 10-year follow-up to determine the patterns of disease progression and other comorbidities. During the follow-up period, 158 of 470 patients with MGUS (33.62%) progressed to symptomatic monoclonal gammopathies. Most of these were multiple myeloma (134/470 patients, 28.51%), and those diagnosed within 2 years after diagnosis of MGUS was high. Approximately 30–50% of patients with MGUS had hypertension, diabetes, hyperlipidemia, and osteoarthritis at the time of diagnosis, and these comorbidities were newly developed during the follow-up period in approximately 50% of the remaining patients with MGUS. Approximately 20–40% of patients with MGUS have acute or chronic kidney failure, thyroid disorders, disc disorders, peripheral neuropathy, myocardial infarction, stroke, and heart failure during the follow-up period. Altogether, when MGUS is diagnosed, close follow-up of the possibility of progression to multiple myeloma is required, especially within 2 years after diagnosis; simultaneously, various comorbidities should be considered and monitored during the follow-up of patients with MGUS. Continuous research is needed to establish appropriate follow-up guidelines. Nature Publishing Group UK 2021-09-16 /pmc/articles/PMC8445957/ /pubmed/34531426 http://dx.doi.org/10.1038/s41598-021-97664-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Kang, Ka-Won Song, Ji Eun Lee, Byung-Hyun Jeon, Min Ji Yu, Eun Sang Kim, Dae Sik Lee, Se Ryeon Sung, Hwa Jung Choi, Chul Won Park, Yong Kim, Byung Soo A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea |
title | A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea |
title_full | A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea |
title_fullStr | A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea |
title_full_unstemmed | A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea |
title_short | A nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in South Korea |
title_sort | nationwide study of patients with monoclonal gammopathy of undetermined significance with a 10-year follow-up in south korea |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445957/ https://www.ncbi.nlm.nih.gov/pubmed/34531426 http://dx.doi.org/10.1038/s41598-021-97664-y |
work_keys_str_mv | AT kangkawon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT songjieun anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT leebyunghyun anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT jeonminji anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT yueunsang anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT kimdaesik anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT leeseryeon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT sunghwajung anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT choichulwon anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT parkyong anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT kimbyungsoo anationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT kangkawon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT songjieun nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT leebyunghyun nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT jeonminji nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT yueunsang nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT kimdaesik nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT leeseryeon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT sunghwajung nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT choichulwon nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT parkyong nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea AT kimbyungsoo nationwidestudyofpatientswithmonoclonalgammopathyofundeterminedsignificancewitha10yearfollowupinsouthkorea |